604 related articles for article (PubMed ID: 15838627)
1. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
2. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
3. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
6. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
7. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
9. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
10. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
11. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
[TBL] [Abstract][Full Text] [Related]
12. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
13. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
[TBL] [Abstract][Full Text] [Related]
14. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
[TBL] [Abstract][Full Text] [Related]
15. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
Bettembuk P; Balogh A
Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
[TBL] [Abstract][Full Text] [Related]
16. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Uzawa M
Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
[TBL] [Abstract][Full Text] [Related]
17. Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis.
Vlasiadis KZ; Damilakis J; Velegrakis GA; Skouteris CA; Fragouli I; Goumenou A; Matalliotakis J; Koumantakis EE
Maturitas; 2008 Mar; 59(3):226-33. PubMed ID: 18342460
[TBL] [Abstract][Full Text] [Related]
18. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R
J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
[TBL] [Abstract][Full Text] [Related]
19. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
Sanad Z; Ellakwa H; Desouky B
Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
[TBL] [Abstract][Full Text] [Related]
20. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]